HOUSTON, August 14, 2025 — Leads & Copy — Moleculin Biotech, Inc. (Nasdaq: MBRX) will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, held virtually from August 19-21, 2025. Walter Klemp, Founder, President, CEO, and Chairman of Moleculin, will present on Wednesday, August 20, 2025, at 2:00 PM ET.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing therapeutic candidates for hard-to-treat tumors and viruses. Its lead program, Annamycin, targets relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. The company has initiated the MIRACLE Trial (MB-108) to evaluate Annamycin in combination with cytarabine for AML treatment.
Additionally, Moleculin is developing WP1066, an Immune/Transcription Modulator, for brain tumors, pancreatic, and other cancers, along with a portfolio of antimetabolites, including WP1122, for potential treatment of pathogenic viruses and cancer indications.
Jenene Thomas
JTC Team, LLC
(908) 824-0775
MBRX@jtcir.com
Source: Moleculin Biotech, Inc.
